Effects of ciprofloxacin concentrations on the resistance of uropathogen *Escherichia coli*: in vitro kinetics and dynamics simulation model

Maya Dian Rakhmawatie¹*, Mustofa², Eti Nurwening Sholikhah²

¹Department of Biomedical Sciences, Faculty of Medicine, Universitas Muhammadiyah Semarang, Semarang, Indonesia, ²Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia

ABSTRACT

Ciprofloxacin is recommended for complicated urinary tract infection (UTIs) caused by multidrug-resistant pathogens included *Escherichia coli*. However, its optimum dose for UTIs remains uncertain that may cause the bacterial resistance. This study was conducted to evaluate the effects of ciprofloxacin concentrations on the resistance of *E. coli*. The in vitro pharmacokinetic/pharmacodynamic (PK/PD) models of ciprofloxacin 750 mg oral dose twice a day for one day was compared to that dose of 500 mg twice a day for three days. Pharmacokinetic parameters i.e. AUC₀-24, Cmax, and pharmacodynamic parameter i.e. MIC of ciprofloxacin against *E. coli* which previously had MIC of 0.5 µg/mL were determined. The PK/PD parameters combination of ciprofloxacin included AUC₀-24/MIC, Cmax/MIC, and T>MIC ratio were used to evaluate its antimicrobial activities which was measured based on kill and re-growth rates of bacterial colony after the ciprofloxacin administration. The result showed that MIC value against *E. coli* increase to 8-16 and 32-64 µg/mL after ciprofloxacin 750 and 500 mg administration, respectively, indicating the emergence of resistance. Both doses of ciprofloxacin were able to reduce the number of bacterial colony in the first two hours administration. However, after two hours administration, those both doses could make re-growth of bacterial colony. The value of AUC₀-24/MIC (120.42±1.27 vs. 92.62±9.36), Cmax/MIC (4.75±0.21 vs. 3.26±0.30), and T>MIC 89.58±7.22 vs. 76.39±9.39 after ciprofloxacin administration at dose of 750 mg were higher than those at dose of 500 mg. The increase of AUC₀-24/MIC and Cmax/MIC values could reduce the number of bacteria colony, however could not for T>MIC value. In conclusion, the AUC₀-24/MIC and Cmax/MIC parameters of ciprofloxacin can be used to evaluate its activity. In addition, ciprofloxacin twice per day at dose 500 mg for three days and 750 mg for one day are not different in the inhibition of *E. coli* resistance emergence.

**Keywords:** ciprofloxacin; pharmacokinetic; pharmacodynamics- *E. coli*; resistance;

Submitted : 2019-07-23
Accepted : 2020-05-24

*corresponding author: mayapriambodo83@gmail.com mayadianr@unimus.ac.id
INTRODUCTION

New antibiotic discovery and development have slowed alarmingly in recent decades. Otherwise, bacterial resistance to antimicrobial agents is a growing problem due to not optimal of the dose regimen of the antimicrobial agents. Therefore, effort to optimize the dose regimen of antimicrobial agent is urgently needed in order to obtain optimal clinical benefit and minimize the risk of multidrug resistant bacterial pathogens. To obtain the optimal of the dose regimen, linking the concentration-time course at the site of action and the antibiotic susceptibility (pharmacokinetic and pharmacodynamic relationship) should be considered.

In vivo pharmacokinetic and pharmacodynamic relationship (PK/PD) models of an antibiotic could be conducted in animal. The in vivo PK/PD models provide similar growing conditions for bacteria, closely imitating the characteristics of a human infection, and clearly defining the endpoint of an infection (cure or death) and comparable to that in humans. A significant disadvantage of animal models is differences in the PK, which limit sophisticated scaling methods for transferring data from animals to humans.

In vitro PK/PD models have its own advantages. This models can be applied without influenced by bacterial phenotype at the site of infection, in vivo bacterial growth phase, host immunity, infection site, and pharmacokinetics of the antibiotics. In addition, this method allows resistance analyses, determination of time-kill behaviour, and identification and optimization of PK/PD indices and breakpoints. Therefore, the in vitro PK/PD models are often applied before the in vivo PK/PD models conducted.

Urinary tract infection (UTI) is an infection that affects part of the urinary tract. The UTIs occur more commonly in women than men, with half of women having at least one infection in their lifetimes. The most common cause of UTIs is *Escherichia coli* which reaches 80% of UTI cases. Amoxicillin has traditionally been a first-line antibiotic for UTI, however increased rates of *E. coli* resistance have made it a less acceptable choice. Fluoroquinolones is useful for UTIs caused by multidrug-resistant pathogens. Ciprofloxacin has been recommended for complicated UTIs and pyelonephritis caused by *E. coli* in patients one to 17 years old.

The dose regimens of ciprofloxacin for UTIs were investigated by some authors. However the optimum dose regimen of ciprofloxacin for UTIs remains uncertain. Ciprofloxacin can be administered in doses of 500 mg twice per day or 1000 mg once per day for seven days. In addition, ciprofloxacin dose of 400-500 mg twice per day for 10-14 days has been recommended. Although in short-course therapy for seven days with the same dose of the ciprofloxacin is effective for the treatment of uncomplicated UTIs.

Milo et al. reported no difference in outcome regarding symptoms between 3-day and 5-10 day antibiotic regimens for uncomplicated UTI in women. However, the longer regimen was more common in adverse effects although it was more effective at eradicating bacteriuria. Furthermore, Lutters and Vogt-Ferrier reported that resolution of short-term bacteriuria of UTI in older women was better in the longer course treatment group compared with the shorter term treatment group. However, there was no difference in long-term bacteriuria or clinical cure rate.

This study was conducted to evaluate the effects of ciprofloxacin
concentrations on the resistance of uropathogen E. coli. The in vitro PK/PD models of ciprofloxacin oral dose of 750 mg twice per day for one day was compared to that dose of 500 mg twice per day for three days in this study.

MATERIALS AND METHODS

Strains and antibiotic

Escherichia coli strain isolated from urinary tract infection patients was used in this study. The uropathogenic E. Coli isolate was identified and cultured in Laboratory of Department of Microbiology, Faculty of Medicine, Universitas Muhammadiyah Semarang. Furthermore, susceptibility of the E. coli strain to ciprofloxacin was determined using broth dilution method. The E. coli strain was ciprofloxacin-sensitive strain with MIC value of 0.5mg/mL according to EUCAST. Ciprofloxacin was obtained from pharmaceutical companies PT Phapros Tbk Semarang, Indonesia. Ciprofloxacin stock solution was prepared with 4% NaOH in sterile distilled water and stored at 4°C before use.

MIC determination

The MIC of ciprofloxacin against uropathogenic E. Coli isolate was determined using the microdilution method according to the laboratory standard guideline. Bacteria from clones were picked from freshly culture plates and then diluted with Mueller-Hinton Broth (MHB) liquid media to final concentration of 10⁶ CFU/mL. Serial dilutions of ciprofloxacin ranged from 0.008 to 32 µg/mL were then prepared by diluting the stock solution with MHB media. One hundred uL of the diluted bacterial suspension was added to tube containing 1900 uL of the serial dilutions of ciprofloxacin to yield the appropriate density (5x10⁶ CFU/mL) and the incubated for 18 to 24 h at 37°C. As control was a tube containing the diluted bacterial suspensions without ciprofloxacin. MICs were defined as the lowest concentration of ciprofloxacin that completely inhibits the growth of the organism as detected by the unaided eye.

In vitro kinetic model

An in vitro kinetic one-compartment model as described previously was used to simulate the serum ciprofloxacin-time curve in humans. The model consists of fresh medium reservoir, central compartment, and liquid waste storage compartment (FIGURE 1). The medium is pumped from the fresh medium reservoir to the central compartment by a peristaltic pump. A filter membrane with pore size of 0.45 µm is placed at the bottom of central compartment to prevent bacteria from flowing out with the medium. A magnetic stirrer is attached to the central compartment, ensuring homogenous mixing of the culture and preventing the membrane pores being blocked by bacteria. The central compartment has also sampling port to facilitate repeated sampling. During the experiments, the apparatus was placed in a thermostatic room at 35°C. Fresh MHB medium pumped into the central compartment displaces an equal volume of liquid, which flows out through and enters the waste medium container.
Ciprofloxacin added to the central compartment was diluted according to the first order kinetics \( C = C_{\text{max}} \times e^{-kt} \), where \( C \) was the ciprofloxacin concentration at time \( t \), \( C_{\text{max}} \) was the initial antibiotic concentration, \( k \) was the rate of elimination and \( t \) was the time elapsed since ciprofloxacin addition.

Pharmacokinetics in healthy volunteers receiving oral dose of ciprofloxacin (750mg twice per day for one day and 500mg twice per day for three days) were simulated in this study.

**In vitro PK/PD study of ciprofloxacin**

The culture of *E. coli* isolates in concentration of \( 5 \times 10^8 \) CFU was added to the central compartment containing fresh MHB medium and then incubated at 35°C for three days. Followed after this incubation period, the ciprofloxacin at concentration corresponding to a dose of 750mg twice per day for one day or 500mg twice per day for three days were added into the central compartment and the pump was turned on.

For the PD analysis, a 200µL sample was then taken through the sampling port at the following time points: 0, 0.5, 1, 1.5, 2, 4, 7, 11, 12, 12.5, 13, 13.5, 15, 23, 24, 26 and 28 h for the dose of ciprofloxacin of 750mg and 0, 0.5, 1, 1.5, 2, 4, 7, 11, 12, 12.5, 13, 13.5, 15, 23, 24, 24.5, 25, 25.5, 36, 36.5, 37, 37.5, 48, 48.5, 49, 49.5, 60, 60.5, 61, 61.5 and 72 h for the dose of ciprofloxacin of 500mg. The sample was stored at 2-8°C until the ciprofloxacin concentration was determined.

**Determination of ciprofloxacin concentration**

The determination of ciprofloxacin concentration was performed using a high performance liquid chromatography (HPLC) method. The HPLC instrument (Shimadzu, Kyoto, Japan) was equipped with a model series LC-10 AD VP, Rheodyne 7725i injector with a 100µL loop and SPD-10A UV-
Visible detector. A reversed-phase C$_{18}$ column ( Eurospher; 4.6µm, 250mm x 4.6mm i.d) was used as the stationary phase for separation and quantitation. The mobile phase consisted of phosphate buffer-acetonitrile-triethylamine (65:35:0.6 v/v/v) pH adjusted to 3.0 ± 0.05 with phosphoric acid. A flow rate of 0.8mL/min was maintained. The injection volume was 20µL. The detector was set at 275nm. A 200µL sample was precipitated with 200µL acetonitrile and then was vortexed for one min. After centrifugation at 5000 rpm for 10 min, the supernatant was transferred to a 2-mL polyethylene tube and 20µL of the supernatant was injected into the HPLC system. All assays were conducted in triplicate and the correlation coefficient for standard curves was always ≥0.99. The lower limit of quantitation was 4.12µg/mL and the coefficient of variation was 7.06%.

**PK/PD analysis**

The pharmacokinetic data included $C_{\text{max}}$ (the maximum concentration of ciprofloxacin in central compartment), $AUC_{0-24}$ (the area under the concentration-time curve for ciprofloxacin from h 0 to 24), $T>MIC$ (the percentage of a 24-h period in which the ciprofloxacin concentration exceeds the MIC) were calculated using standard method. Furthermore, the PK/PD parameters included $C_{\text{max}}$/MIC, $AUC_{0-24}$/MIC and $T>MIC$ were determined using the pharmacokinetic values and MIC data in each experiment. The relationship between the PK/PD parameters and a log $E.\ coli$ colony at final phase of growth rate as well as of final phase of the kill rate were evaluated.

Data were expressed as the mean ± standard deviation (SD). Statistical comparisons were conducted using Student’s t-test. The differences between the parameters after ciprofloxacin oral dose of 750mg and 500mg were considered significant at a value of <0.05.

**RESULTS**

**MIC of ciprofloxacin against $E.\ coli$ isolates**

The original MIC of ciprofloxacin against uropathogenic $E.\ coli$ isolates was 0.5µg/mL. With this MIC value, the isolates was considered susceptible to ciprofloxacin. After ciprofloxacin addition at concentration corresponding to a dose of 750mg twice per day for one day or 500mg twice per day for three days, the isolates developed loss of susceptibility with MICs ranging from 8.0 to 16.0µg/mL and from 32.0 to 256.0µg/mL, respectively.

**In vitro pharmacokinetic profile**

In vitro pharmacokinetic profile of ciprofloxacin at dose of 750mg twice per day for one day and at dose of 500mg twice per day for three days is presented in FIGURE 2, where as their pharmacokinetic values are presented in TABLE 1.
In vitro pharmacokinetic profile of ciprofloxacin at A) dose of 750mg twice per day for one day and B) dose of 500mg twice per day for three days

**In vitro pharmacodynamic profile**

In vitro pharmacodynamic profile of ciprofloxacin at dose of 750mg twice per day for one day and at dose of 500mg twice per day for three days as well as control is presented in FIGURE 3. The number of bacterial colonies significantly decreased at the first two hours after ciprofloxacin administration at doses of 750 and 500mg and then significantly increased two hours after ciprofloxacin administration (p<0.05). Moreover, the *E. coli* growth rate after ciprofloxacin at dose of 750 mg was significantly lower than that at dose of 500mg (p<0.05). In contrast, the number of bacterial colonies significantly increased during control administration. It was indicated that the *E. coli* kill rate phase is observed at the first two hours, where as the *E. coli* re-growth rate phase is observed after two hours of ciprofloxacin administration.
The kill rate slope 2 hours and re-growth rate slope on 1 day were analyzed. The results are presented in TABLE 3-5 and FIGURE 4-6.

A positive relationship between AUC\(_{0-24}\)/MIC with the number of log *E. coli* colony at the final phases of growth rate and kill rate was observed (TABLE 3 and FIGURE 4). The increase of the AUC\(_{0-24}\)/MIC ratio might increase the antimicrobial activity of ciprofloxacin as indicated by greater decreased in the number of log *E. coli* colony.
TABLE 3. AUC<sub>0-24</sub>/MIC parameters of dose of ciprofloxacin 500 and 750mg and the decrease or increase in the number of log E. coli colony kill rate and growth rate phases

| Ciprofloxacin | AUC<sub>0-24</sub>/MIC | Log colony decrease in kill rate phase | Log colony increase/decrease in growth rate phase |
|---------------|-------------------------|----------------------------------------|-------------------------------------------------|
| Dose 500mg    |                         |                                        |                                                 |
| 1             | 86.00                   | 2.62                                   | -2.51                                           |
| 2             | 99.24                   | 2.63                                   | -3.27                                           |
| 3             | 74.48                   | 2.72                                   | -3.16                                           |
| Mean ± SD     | 92.62±9.36              | 2.625±0.007                            | -2.89±0.537                                     |
| Dose 750mg    |                         |                                        |                                                 |
| 1             | 121.32                  | 3.02                                   | 0.10                                            |
| 2             | 119.52                  | 3.20                                   | -0.38                                           |
| 3             | 114.66                  | 3.20                                   | 0.06                                            |
| Mean ± SD     | 120.42±1.27             | 3.11±0.13                              | -0.14±0.34                                      |

FIGURE 4. Linear regression relationship between AUC<sub>0-24</sub>/MIC and the number of log E. coli colony at final phase of the growth rate (A) Linear regression relationship between AUC<sub>0-24</sub>/MIC and the number of log E. coli colony at final phase of the kill rate (B)

A positive relationship between Cmax/MIC with the number of log E. coli colony at the final phases of growth rate and kill rate was also observed (TABLE 4 and FIGURE 5). However, significantly different in the phase of kill rate at 2 hours after ciprofloxacin administration at dose of 750mg and that of 500mg was observed. The Cmax at dose of 750mg was significantly higher than that at dose of 500mg resulting higher Cmax/MIC ratio and higher antimicrobial activity as demonstrated by the greater decrease in the number of log E. coli colony in the first 2 hours ciprofloxacin administration.
TABLE 4. Cmax/MIC parameters of dose of ciprofloxacin 500 and 750mg and the value respectively decrease or increase in the number of log E. coli colony kill rate and growth rate phases

| Ciprofloxacin | C_{max}/MIC | Log colony decrease in kill rate phase | Log colony increase/decrease in growth rate phase |
|---------------|-------------|---------------------------------------|--------------------------------------------------|
| Dose 500mg    |             |                                       |                                                  |
| 1             | 3.22        | 2.62                                 | -2.51                                            |
| 2             | 3.58        | 2.63                                 | -3.27                                            |
| 3             | 2.98        | 2.72                                 | -3.16                                            |
| Mean ± SD     | 3.26±0.30   | 2.66±0.05                            | -2.98±0.41                                       |
| Dose 750mg    |             |                                       |                                                  |
| 1             | 4.86        | 3.02                                 | 0.10                                             |
| 2             | 4.88        | 3.20                                 | -0.38                                            |
| 3             | 4.50        | 3.20                                 | 0.06                                             |
| Mean ± SD     | 4.75±0.21   | 3.14±0.10                            | -0.07±0.27                                       |

FIGURE 5. Linear regression relationship between C_{max}/MIC and the number of log E. coli colony at final phase of the growth rate (A) Linear regression relationship between AUC_{0-24}/MIC and the number of log E. coli colony at final phase of the kill rate (B)
TABLE 5. T>MIC parameters of dose of ciprofloxacin 500 and 750mg and the value respectively decrease or increase in the number of log E. coli colony kill rate and growth rate phases

| Ciprofloxacin | T>MIC | Log colony decrease in kill rate phase | Log colony increase/decrease in growth rate phase |
|---------------|-------|----------------------------------------|-----------------------------------------------|
| **Dose 500mg** |       |                                        |                                               |
| 1             | 77.08 | 2.62                                   | -2.51                                         |
| 2             | 85.41 | 2.63                                   | -3.27                                         |
| 3             | 66.67 | 2.72                                   | -3.16                                         |
| Mean ± SD     | 76.39±9.39 | 2.66±0.05                              | -2.98±0.41                                    |
| **Dose 750mg** |       |                                        |                                               |
| 1             | 93.75 | 3.02                                   | 0.10                                          |
| 2             | 93.75 | 3.20                                   | -0.38                                         |
| 3             | 81.25 | 3.20                                   | 0.06                                          |
| Mean ± SD     | 89.58±7.22 | 3.14±0.10                              | -0.07±0.27                                    |

FIGURE 6. Linear regression relationship between T>MIC and the number of log E. coli colony at final phase of the growth rate (A) Linear regression relationship between AUC0-24/MIC and the number of log E. coli colony at final phase of the kill rate (B)
DISCUSSION

The result of the PK/PD parameters relationship analysis showed the emergence of E. coli resistance after ciprofloxacin at dose of 750mg twice a day for one day or at dose of 500mg twice a day for three days. It was demonstrated by the increase of MIC value against E. Coli to be 8-16 and 32-64µg/mL after ciprofloxacin 750 and 500mg administration, respectively. The both doses of ciprofloxacin administration could not inhibit the emergence of E. coli resistance. Although, the increase of MIC value ciprofloxacin after administration at dose 750mg was lower that at dose 500mg.

The in vitro PK/PD model to evaluate antimicrobial activity of ciprofloxacin against E. coli has been reported previously. Fantin et al.\textsuperscript{15} reported that the resistant commensal E. coli from fecal and pharyngeal emerge during treatment with six dose of ciprofloxacin. However, the resistance emergence is not associated with the PK/PD parameters. The different of AUC/MIC, C\textsubscript{max}/MIC, and T>MIC ratio values does not affect the emergence of E. coli resistance which not indicate significantly different across the different ciprofloxacin dosages. Khan et al.\textsuperscript{16} developed an in vitro PK/PD model describing killing kinetics for E. coli following exposure to ciprofloxacin. This model successfully characterizes time-kill curve for both will type and the six E. coli mutants based on the MIC of ciprofloxacin.

Antibiotic resistance can occur due to three main mechanisms as follow 1) the transfer of resistant genes from resistant to susceptible micro organisms; 2) genetic adaptation (changing the drug target); and 3) phenotype adaptation, such as modification of efflux pumps. Resistance mechanisms of genetic and phenotypic adaptation can be triggered by de novo resistance that occurs quickly during therapy.\textsuperscript{17,18}

Escherichia coli could be resistant to multiple antibiotics during minimal exposure of antibiotics levels due to horizontal gene transfer (HGT) of resistant strains to susceptible strains. Resistance is often associated with a reduction in ‘fitness’ of bacteria, which means the ability of a genotype or individuals of bacteria to survive and reproduce. Decreased use of antibiotics will reduce the environmental pressure on the bacteria and reduce the amount of acquired resistance. The speed of bacterial resistance is affected by the speed of de novo mutations and HGT from carrier of resistance determinants. The most frequent mutation is to change the target action of antibiotics and increasing antibiotic efflux. Gene amplification, decreased gene expression of the target antibiotics, and changes enzymes for the drugs modification are other mechanisms involving in microbial resistance. HGT-related mechanisms include modification of the drug itself, the target protection, bypass resistance (change in metabolic phase that inhibited by antibiotic), and the acquisition of efflux pumps. The increase MIC value to ≥ 32µg/mL against E. coli is associated with mutations of gyrA and parC or a combination mutation of marR, gyrA, and parC. Where as, the MIC value < 1µg/mL is associated with gyrA gene mutation alone or mutation combination of marR and gyrA.\textsuperscript{19} In addition, it was reported that de novo E. coli resistance is associated with the sub optimal concentration due to enfloksasin use as demonstrated by the increase of its MIC value.\textsuperscript{20} Some studies reported that the ratio of C\textsubscript{max}/MIC and AUC\textsubscript{0-24}/MIC should reach between 10-12 and 100-125, respectively to achieve therapeutic efficacy of fluoroquinolones against Gram – bacilli infections and to prevent emergence of resistance.\textsuperscript{21} The emergence of Gram-bacilli resistance 80% to ciprofloxacin was reported when the ratio of C\textsubscript{max}/MIC and AUC\textsubscript{0-24}/MIC < 8 and < 100, respectively. This emergence of resistance decreased to be 10% (8 time
prevention), if the ratio of $C_{\text{max}}$/MIC and $\text{AUC}_{0-24}$/MIC $> 8$ and $\geq 100$, respectively.\textsuperscript{22} Other study reported that the ratio of $\text{AUC}_{0-24}$/MIC $<100$ cause 86% of developed patient resistance, however if the ratio $\geq 100$, the incidence of resistance decrease to be 9%. The emergence of resistance is an important factor ofa clinical failure therapy.\textsuperscript{23} It was reported that the ratio $\text{AUC}_{0-24}$/MIC should be $>250$ to provide the rapid Gram-bacilli elimination.\textsuperscript{24}

In this study, the ratio of $C_{\text{max}}$/MIC was $< 8$ after administration of ciprofloxacin at dose of 500 and 750mg. Although the ratioof $\text{AUC}_{0-24}$/MIC was $>100$ at dose of 750mg, it could not prevent the emergence of uropathogen \textit{E. coli} resistance. Moreover, a regrowth rate phase of uropathogen \textit{E. coli} was still observed at dose of 750mg.

Zelenitsky and Ariano\textsuperscript{25} reported that among 178 \textit{Enterobacteriacea} infection cases treated with ciprofloxacin, 8 cases had failed therapy with 3 cases of them (37.5%) were infection of uropathogen \textit{E. coli}. The treatment failure might be due to low the ratio of $\text{AUC}_{0-24}$/MIC of ciprofloxacin. The ratio of $\text{AUC}_{0-24}$/MIC $\geq 250$ indicated the success of therapy (success rate 91.4%). If the ratio decreased to be$< 250$, the risk of treatment failure increased 27.8 times higher.

CONCLUSION

In conclusion, the $\text{AUC}_{0-24}$/MIC and $C_{\text{max}}$/MIC parameters of ciprofloxacin can be used to evaluate its antimicrobial activity against uropathogen \textit{E. coli}. In addition, ciprofloxacin twice per day at dose 500mg for three days and 750mg for one day are not different in the inhibition of \textit{E. coli} resistance emergence.

ACKNOWLEDGEMENTS

We would like to thank the technicians who have gave valuable assistance during the study.

REFERENCES

1. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobial. Clin Infect Dis 2007; 45(1):89-95. https://doi.org/10.1086/518137
2. Onufrik NJ, Forrest A, Gonzales D. Pharmacokinetic and pharmacodynamic principles of anti-infectivedosing. Clin Ther 2016; 38(9):1930-47. https://doi.org/10.1016/j.clinthera.2016.06.015
3. Gloede J, Scheerans C, Derendorf H, Kloft C. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother 2010; 65(2):186-201. https://doi.org/10.1093/clinchem/hvp082
4. Zhao M, Lepak AJ, Andes DR. Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents. Bioorg Med Chem 2016; 24(1):6390-400. https://doi.org/10.1016/j.bmc.2016.11.008
5. Dudley MN, Griffith D. Animal models of infection for the study of antibiotic pharmacodynamics. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel Dekker, Inc., 2002: 67–98.
6. McLain JE, Cytryn E, Durso LM, Young S. Culture-based methods for detection of antibiotic resistance in agroecosystems: advantages, challenges, and gaps in knowledge. J Environ Qual 2016; 45(Special Section):432-40. https://doi.org/10.2134/jeq2015.06.0317
7. Hooton TM. Uncomplicated urinary tract infection. N Eng J Med 2012; 366(11):1028-37. https://doi.org/10.1056/NEJMcp1104429
8. White B. Diagnosis and treatment of urinary tract infections in children. Am Fam Physician 2011; 83(4):409-15.
9. Colgan R, Williams M. Diagnosis and
treatment of acute pyelonephritis in women. Am Fam Physician 2011; 84(5):519-26.
10. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics 2006; 118(3):1287-92. https://doi.org/10.1542/peds.2006-1722
11. Shoff WH, Green-McKenzie J, Edwards C, Behrman AJ, Shepherd SM. Acute pyelonephritis: the differential diagnosis and workup. March 5, 2010. [cited 2013, June 17] Available from: http://emedicine.medscape.com/article/245559.
12. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan C, Miller LG, et al. International clinical practice guideline for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the infectious disease society of america and the european society for microbiology and infectious disease. Clin Infect Dis 2011; 52(5):103-20. https://doi.org/10.1093/cid/ciq257
13. Milo G, Katchman E, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2005; 18(2):004682. https://doi.org/10.1002/14651858.CD004682.pub2
14. Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev 2008; 19(4):001535. https://doi.org/10.1002/14651858.CD001535.pub2
15. Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, et al. Ciprofloxacin dosage and emergence of resistance in human comensal bacteria. J Infect Dis 2009; 200(3):390-8. https://doi.org/10.1086/600122
16. Khan DD, Lagerbak P, Cao S, Lustig U, Nielsen EI, Cars O, et al. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic from MIC values for WT and mutants. J Antimicrob Chemother 2015; 70(11):3051-60. https://doi.org/10.1093/jac/dkv233
17. Reygaert W. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol 2018; 4(3):482-501. https://doi.org/10.3934/microbiol.2018.3.482
18. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr 2016; 4(2):10.1128/microbiolspec.VMBF-0016-2015 https://doi.org/10.1128/microbiolspec.VMBF-0016-2015
19. Andersson DI, Hughes, D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8(4):260-71. https://doi.org/10.1038/nrmicro2319
20. Vander Horst MA, Schuurmans JM, Smid MC, Koenders BB, ter Kuile BH. De novo acquisition of resistance to three antibiotics by Escherichia coli. Microb Drug Resist 2011; 17(2):141-7. https://doi.org/10.1089/mdr.2010.0101
21. Novelli A, Rosi E. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemother 2017; 29(1):10-8. https://doi.org/10.1080/1120009X.2017.1380357
22. Peloquin CA, Cumbo TJ, Nix DE, Sand MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infection, Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989; 149(10):2269-73.
23. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH,
et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42(3):521-7.

24. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 (Suppl.3):S233-7.

25. Zelenitsky SA & Ariano RE. Support for higher ciprofloxacin AUC$_{0-24}$/MIC targets in treating Enterobacteriacea bloodstream infection. J Antimicrob Chemother 2010; 65(1):1725-32.

https://doi.org/doi:10.1093/jac/dkq211